Revolution Medicines (RVMD) Q1 FY26 earnings call

Revolution Medicines reported a pivotal quarter, highlighted by daraxonrasib's unprecedented overall survival benefit in previously treated metastatic pancreatic cancer, validating its RAS(ON) inhibitor strategy. The company secured significant capital to advance its broad pipeline of four clinical-stage RAS(ON) inhibitors and next-generation catalytic inhibitors. Efforts are now focused on urgent regulatory filings and commercialization readiness for daraxonrasib, while also progressing multiple registrational studies across pancreatic cancer and non-small cell lung cancer.